Sacubitril/valsartan as first-line therapy in anthracycline-induced cardiotoxicity

Kardiol Pol. 2021;79(9):1040-1041. doi: 10.33963/KP.a2021.0052. Epub 2021 Jul 6.

Authors

Rafał Dankowski¹, Wioletta Sacharczuk², Anna Łojko-Dankowska³, Anna Nowicka², Anna Szałek-Goralewska², Andrzej Szyszka²

Affiliations

¹ 2nd Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland. rafaldan@ump.edu.pl.
² 2nd Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland.
³ Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznań, Poland.

PMID: 34227674
DOI: 10.33963/KP.a2021.0052

No abstract available

MeSH terms

Aminobutyrates / adverse effects
Anthracyclines* / adverse effects
Biphenyl Compounds
Cardiotoxicity* / etiology
Drug Combinations
Humans
Valsartan

Substances

Aminobutyrates
Anthracyclines
Biphenyl Compounds
Drug Combinations
Valsartan
sacubitril and valsartan sodium hydrate drug combination